Worldwide Optimizes Data Quantity & Quality in Mucopolysaccharidoses Research Studies

Mucopolysaccharidoses is a rare congenital condition characterized by an impairment of the body’s ability to break down mucopolysaccharides, leading to a buildup of sugars in the cells, blood, and connective tissue. The disorder has been associated with severe morbidity and reduced life expectancy. Although mucopolysaccharidoses is present at birth, its effects often don’t emerge until later as the tissues grow and the individual begins to experience pain, impaired motor and sensory function, and, in some cases, impaired intellectual development or behavioral issues. For researchers, there is a challenge associated with patient and caregiver burden, due to pain, fatigue, and psychological impacts of the disease.

For the complexities of rare and challenging conditions, you’ll want the resources of a full-service CRO partner like Worldwide Clinical Trials on your side. Harness our expertise in study design to identify the most appropriate outcome measures and assessment instruments to suit your research goals. Our access to global patient populations, combined with our understanding of regional variations in standards of care and regulatory considerations, means we can optimize both data quantity and quality.

We are an internationally acclaimed expert in clinical trial management. We offer full-service support for Phase I-Phase IV clinical trials, as well as real-world evidence studies that can help you understand the effects of your work over both the short and long term.

When you’re ready to take your research to the next level, talk to Worldwide.